Alto Neuroscience, Inc. (ANRO)

Market Cap	104.91M
Revenue (ttm)	n/a
Net Income (ttm)	-57.45M
Shares Out	26.97M
EPS (ttm)	-3.05
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	278,003
Open	3.650
Previous Close	3.720
Day's Range	3.650 - 3.930
52-Week Range	3.560 - 24.000
Beta	n/a
Analysts	Strong Buy
Price Target	19.67 (+405.66%)
Earnings Date	Feb 2, 2025

About ANRO

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 2, 2024
• Employees: 67
• Stock Exchange: NYSE
• Ticker Symbol: ANRO
• Website: https://www.altoneuroscience.com

Analyst Forecast

According to 6 analysts, the average rating for ANRO stock is "Strong Buy." The 12-month stock price forecast is $19.67, which is an increase of 405.66% from the latest price.

Price Target

$19.67

(405.66% upside)

Analyst Consensus: Strong Buy